May 6, 2024 — Cannabis Licensing Advisory Board Regular Meeting

Transcript

Captions from City of Boulder YouTube recording.

[0:00] But G. Welcome to the May 6. meeting of the City of Bowlers, cannabis, Licensing Advisory Board. let's go ahead and start with instructions for virtual meeting, and rules up to car. Perfect. Thank you. Good afternoon. The city has engaged with community members to co-create a vision for productive, meaningful, and inclusive civic conversation. This vision supports physical and emotional safety for community members, staff and board and commission members as well as democracy. For people of all ages, identities lived experiences and political perspectives. More about this vision and the project's community engagement process could be found on the link on your screen. The following are examples of rules of decorum found in the boulder revised code and other guidelines that support this vision. These will be upheld during the meeting.

[1:07] All remarks and testimony shall be limited to matters related to city business. No participant shall make threats or use other forms of intimidation against any person. obscenity, racial epithets, and other speech and behavior that disrupts or otherwise impedes the ability to conduct the meeting are prohibited. participants are required to sign up to speak, using the name they are commonly known by, and individuals must display their whole name before being allowed to speak online. The QA function should only be used for technical questions to staff, and will not be used for public comment. Okay, would you like to go ahead and do roll, call. Absolutely. Before I do roll call, we do have one item. 2 items. Actually, Member Green did email us, and she will be out due to a family matter today.

[2:02] And Member Christy resigned. Effective. May first, and he wanted to let you all know that he wishes you all well. all right. Roll call member Foster. Sorry Present. Thank you. Vice chair. Keegan. Present. Sure kunstman. Present. Member, noble. Present. Ex Officio member Thompson. Present. Exofficio member Decalo. Present. Sure you have a quorum. Okay? So let's take a look at the April first minutes. Does anyone have any concerns or questions? Go ahead, Adam. There is a minor typo under item 9

[3:01] there's a place where it says HEH. And I think it's supposed to be the word V. Everything else looked correct to me. Good catch on. I'm trying to find it. I guess. Spell check didn't. Didn't find that. Huh? Sincere apologies for the typo. Whoever was was writing it was laughing right, heh! I. I don't think it would affect the substance, but it just it caught my eye. One thing you could do is you could make a motion to move with the a motion to approve with those amendments being made that occasionally happens with the Bla. Alright. That's. A good idea I'd I would make that motion, unless you know, unless there's further a discussion.

[4:01] Brian seconds Adam's motion. For the minutes, with that amendment. Any further discussion. then we have a motion, and a second all in favor. Raise your hand. Internet. that me that leaves no one to abstain or oppose, so. So unfortunately. It's not recorded on the audio version can for raising a pans. Okay. so do you want? Yeah, yeah, in May. That would suffice. You wanna do a rope? No, we don't need to do a rope. Call any all in favor. Yay! A. Yay! Any opposed or abstaining. Okay, thanks. Perfect. Thank you. Okay, I've got item, 2 general public comments for the board. Do we have. So this is now the time for General Pop. Public comments to the board.

[5:03] If you are here to make general public comment, please raise your hand, and you will be admitted as a speaker I will display a 3 min timer. Is there anyone that wishes to speak during general public comment. If you're looking to use the raise hand feature, you can go under the more if you don't see the reactions tab to raise hands. Is there anyone for general public? Comment? Chair Kunstman, I'm not seeing any hands raised. Okay. do we have written comments from the cannabis and Enforcement officer. No, we do not. Unfortunately she could not attend today as well. However, she did give me the following information, if you're ready to receive.

[6:00] True. They have. She has done one round of compliance checks completed with no issues. Boulder PD. Did have 3 DUID marijuana arrests. and there is an ongoing joint investigation for allegations made by a member of the public of which a copy of that is in your packet. Do we have a place in the agenda where we can address them. It is an informational piece, so you can do that under your matters. unless you would like to to do something with that. No, that's that's a logical place. Don't really agree. I got. and a nod and a thumbs up. and a 2 nods and a thumbs up. Okay, alright, we'll save that for matters from the chair and members of board

[7:02] and excuse me. policies, any policy suggestion form. I didn't see any, but. No, there were no policy suggestion forms received from May for agenda. Item number 4. Okay. Then I guess we're ready to go on to the School of Public Health, and I see. I am letting them in as we speak. One moment. See. And this is John Salmon. I'm unable to start my video. I'm working on. Admitting you now. All right.

[8:02] Great thanks for joining us again. And we I'm not. I did not see any. Things to go along with your presentation today. Is that correct? Oh, we have a presentation. We have Powerpoint. I mean a packet, or anything like that. No, no, we no, we can point you towards where materials can be found. We will. Okay. Great. So if you're set, I'll go ahead and share screen here and we'll get started. So so let me just get the rights to the right spot. Say, Colin, do you have it? I had it all set up, and it's wandered away. Give me a. I can share it if you don't. Yeah, let's see, do you have the newest one up. Yes, I have the the shared, Doc.

[9:00] Yeah. Why don't you go? Why don't you go ahead then? So while we're getting this up, go and say thanks for the opportunity to return and talk with you, and thank you may remember that I actually live in Boulder, where the wind is howling as you know, and joined by my colleague colleen, a member of our team who's focused on the educational activities. So if we go on to the next, and what I'm going to do is give you an update and give some focus on the piece we released in the end of March related to policy matters. But next. So just as a reminder, our website and the

[10:00] the there's access. Here's her. The QR code includes all of our reports and then documents, our activities. So we go to the next our team is substantial. We have a number of activities that we carry out under House Bill 1, 3, 1 7, particularly under the so-called research core, the review activities. And previously, as you know, we've released a very large review of the evidence related to high potency. Marijuana and Thc concentrates as requested under the act, and then also, as requested under the act and colleen, will be giving the update a wide variety of education activities per the bill. We have a scientific Review council that is chaired by Chris Urbina, public health physician and former director of Cdph.

[11:06] next. so current current activities, they're well documented. And now in a monthly newsletter and timeline showing our activities that are on the project website, some of the activities in progress, and part of this is under our broad mandate. We are reaching out to Obju and other providers who deal with pregnancy and young children. In a continuing medical education event with Children's Hospital we planned similar event with psychiatry, probably multiple events to reach out to providers. We have a number of reports in development based on our review mandate, I would highlight a review that's going on covering a substantial body of literature

[12:01] related to cannabis and mental health. We are also planning a review of the pulmonary, the respiratory health health consequences. And then the educational campaign activities that will come to. We're also in response to the many weaknesses we found in the literature that we reviewed, we are convening a group actually in Boulder at the end of June to look at research methods related to cannabis, to try and bring some standardization. One of the problems in the literature is, there's so many ways that people have done their studies asked about the cannabis use. and we don't have the kinds of studies published to now that we really need. And we're looking to the future with this workshop. Next. this is the letter Newsletter and

[13:02] Timeline, showing the advances. And this is available on our website. Next. this is a description of the workshop that I mentioned to improve the state of the literature. We hope others share our concern, and there's a great deal of interest in this workshop, and our intent is to develop materials that will reach the broad scientific literature and have impact next the continuing medical education event. And again, this is something that we will continue to do throughout the State and the region next. and then collaborations with the Department of psychiatry at ants which also has a broad network of providers that and we're working with them to

[14:00] broaden the outreach of our activities next and then, as I mentioned, the literature reviews our intent with the initial review, a so-called scoping review that mapped what literature there is is to update it. and we are updating now the last year's scientific literature, I think, perhaps encouragingly, there's more that seems to be relevant to today's marketplace than previously. And right now we're anticipating adding the findings about 150 new articles to the resource that we have created, and that is available on the web. And again, you can find access to it through our website next. So I've understood that you wanted to focus in, particularly on this report that we wrote on policy approaches. Next, this came out of our mandate. under the language of House Bill 2021, 1, 3, 1, 7,

[15:05] to provide recommendations as we see fit and related to potential regulatory steps. We developed this report in part because some feedback concerning our review of the scientific literature was that we did not say much in part. That was because the literature did not provide a strong and robust foundation for making recommendations with regard to potential policy recommendations. Fortunately, the Literature Review, just highlighted above all the limitations of the literature in hand, particularly in reference to today's marketplace next. And this simply is that reminder about making any recommendations next.

[16:05] So this is the report that we worked on. It's entitled policy Approaches to high concentration. Cannabis and Thc concentrates. And we have several areas that I'll emphasize today. One is that we tried to map those populations that we considered to be particularly potentially at risk. And here we focus on potential harms. We provided, second, a look at the national policy landscape. Third, we look at policy tools that are available, some already in use. And fourth, we describe what are potential options with taking a precautionary approach given that the scientific evidence is not pointing in particular directions.

[17:02] Next. and just the the report's introduction. I'm certainly not going to read this to you sets out this rationale, that, in fact, we look to the scientific literature, and did not find a robust base of evidence. As I have said. In fact, the work that we're undertaking under House Bill 1, 3, 1, 7 was, I think, largely motivated by the recognition that the literature did not point to particular concentration, or those thresholds that might be used in a regulatory framework. Next. So you know, there are potentially many at risk populations, populations needing protection the pregnant woman, the fetus during growth and development during gestation, during breastfeeding. the early life years. youth and young adults. There's attention to older adults because of underlying conditions. Health conditions. Those are preexisting mental health conditions.

[18:10] chronic diseases. Lgbtq plus populations and certain racial and ethnic minority populations, and we recognize that that there are other groups that might be of particular concern, and we are in part using this listing, and it will grow as we receive input for thinking about how to develop and target the educational campaign activities next. And I think, just going to point out that in the report we both try and cite some of the relative relevant evidence, and also, as I'll show you in the table. Look at the population sizes within these groups in Colorado. So pregnancy, breast feeding next

[19:04] use, and young young adults, and we can just go through these quickly, Colin. So older adults and there are plenty of us those pre-existing medical conditions. and then those with underlying chronic diseases. the Lgbtq. Plus populations and various subgroups within our population is defined by racial and ethnic minority designations. And then the table that just gives some idea of the scope and size of these populations is included within within the report. So we've listed. These different groups obtained population estimates. And I think

[20:00] you know, look, when looked at, these are sizable subgroups within our population. No, for example, we have over 62,000 live births per year. A large group of of of people who need to understand the potential risks to the fetus during development of exposure. Next we took a look at the national policy landscape in collaboration with the National Conference of State Legislatures which does a policy database and does policy mapping. And we ask them to look at a State level policies that deal with high concentration cannabis products in some ways, and, as you'll see, there were 22 different policies identified that fell into the 4 categories at the bottom of this slide. Those with concentration, purchase, or possession limits

[21:08] those limiting Thc levels in some way and products purchased for medical use. That was actually 2 states, those that limit THC by product or category. and those that apply a higher tax rate to high concentration cannabis products. So 22 policies identified. This was as of last fall next. And here's just the distribution of those policies across the 4 categories that I just mentioned. and you can see limits by product or category and limits on amount that could be purchased or or possessed next. And this is just we'll just run through these again, patchy across the States, the first category

[22:01] go ahead. second. third, which is our 2 States, and then the fourth. So so again, some States are implementing regulations of different sorts. Next. and then we in this report, review potential policy tools dividing those up into the consumer. Side age restrictions, point of sale restrictions. concentration based taxation and distributor side policy tools. And again, those are listed here, marketing, advertising, restrictions, warning label regulations. concentration caps and limiting products in one way or another, and then in this report, next, we review each of these and touch on the relevant literature again as background. So

[23:02] just I think you can skip through these Colin, too. So these are those now coming then to the situation in Colorado. And again, I think we've shown that the scientific literature is not definitive and pushing towards such measures as a concentration limit or other particular actions. We, in our writing on this in the report have advise a precautionary approach, that is, if we can't assure safety. The best thing to do is to be precautionary, particularly in protecting those groups at risk. Our Scientific Review Council, which is mandated under the bill, has been particularly emphatic about THC. Exposure the fetus during Pregnancy.

[24:00] and pointed to the more general scientific evidence on consequences next. So we turn and man that precautionary approaches be followed in the face of insufficient scientific evidence for pointing a particular policy directions one way or the other. and next. and we talk about if measures are taken. what they should do. And again, a lot of this relates to our emphasis on the at-risk groups, assuring that people understand potential health risks of products that they use even even in the face of uncertainty, and that goes back to yes, people may use certain products. There may be insufficient information on potential risks and other

[25:02] recommendations that might be considered as the scientific evidence grows. I think next is maybe the last one. Let's see. yeah, just just our Last remarks on this, and a lot of what we have found and not found is sort of the basis for the educational campaign activities that Colin is going to describe. So I don't know whether you want to pause now for discussion of what I've presented to the moment, or go on with colleen either works for us. Let me ask the group here. including the ex officio members. I would recommend that the presenters can finish, and then we can have a full Q&A. All the evidence. That's fine!

[26:00] Jonathan. Will this Powerpoint be available to us, or is it available. We can. Certainly. Yeah, we can certainly make this available. Yeah. we'll get that to Kristen. Okay. Sounds good. Thanks, John. I will jump into updates on the educational campaign portion of this project. John kind of already covered this, but the second big part of what the legislation mandated was taking the findings from the scoping review and then putting them into an educational campaign. So we can educate the public about what it learned. Like, John said. The evidence was mixed. So so maybe not so conclusive. So that's kind of our charges, taking what's known about high concentration cannabis and putting it in to practice. Specifically for those target populations that John mentioned of youth as well as pregnant and parenting people.

[27:02] I'll just give a brief overview of just some highlights of the campaign. Our main long term goal is to reduce the use of high concentration cannabis among those target populations I just mentioned. And we're aiming to accomplish that through a multi modal communication campaign. So we're going to leverage different channels to reach our audiences in different ways. So things like social media, that's really everyone, but really targeting that youth population things like podcasts and traditional media as well. So billboards, radio TV, we're really trying to hit all of the all of the marks. We're also partnering with other organizations, like the University of Northern Colorado as well as Csu, to expand the reach of our messages across the State. and then, lastly, a a key point throughout. All of this is that we've engaged community members throughout our entire process to really ensure that our activities and our deliverables are aligning with what the communities actually want.

[28:15] So that said, we started this whole process with doing a series of community advisor workshops. And we did those in 3 different locations, San Luis Valley, Pueblo and Denver. And this is just a snapshot of their main recommendations from that initial round and that was really to get their input, on what messages, how how to frame the messages around cannabis use and high concentration cannabis use as well as where and how to disseminate those messages. So community members really emphasized a need to focus on strengthening youth, mental health and highlighting, healthy coping skills as an alternative for substance use, because we know that telling someone, especially youth, not to use drugs isn't the best way to get a message across.

[29:10] So really focusing on that positive psychology side of things. And then on the bottom, you can see that they also recommended sharing those messages through a range of different avenues, kind of like I mentioned before. So things like going out to community events to share the messages going to pop up events. We're doing some art exhibitions. motivational interviewing, training. So helping people have the tools to have these conversations as well as social media like I mentioned before. So we took all of that feedback from the community members. and incorporated into a series of tool kits that we made based on the evidence from the scoping review that John mentioned. we started by creating these first 3 tool kits that focus on the background of cannabis in general as well as a specific focus on high concentration cannabis

[30:07] and those toolkits. Also highlight, the physical and mental health impacts that cannabis and high concentration cannabis can have for youth and pregnant people. Specifically. there's definitely more of a focus for those populations on what we know about any cannabis use and the health impacts for those populations. Less so on the high concentration side. But we do emphasize the point that the general rule of thumb is that as concentrations increase, the harms are likely to increase as well. And then the fourth. Here, you can see, is the motivational interviewing piece that I just mentioned. And that is going to turn into a series of workshops that really equip people to have conversations around this topic of high con high concentration cannabis. I will mention that these toolkits are not public facing. They're really just serving as the foundation for our other content creation that we're in the process of.

[31:11] Oh, say, okay. So again, we went back to the community after we took that initial feedback made tool kits. Then we brought those back to community members to say, Okay, is this, did we hear you correctly? Are these the type of messages that you want to be hearing? So again, we really wanna ensure that the information that we're putting out there to the public is actually going to be received well by our intended audiences. This is just a snapshot of what we discussed in those workshops. So it was things like what pieces of information are most important to them. What do they think is important to know around high concentration cannabis? Specifically, if anything was missing? And then we also have the focus on positive coping strategies. So what are they actually using in their daily lives to cope with stress instead of turning to cannabis.

[32:04] and then the last piece is what resources do they go to in their community for support? Just to make sure we're hitting the mark on that as well. So we took all that feedback into the toolkits from the community, and, like I said, it serves as the foundation for all of the other work that we have going on now. So we shared those toolkits with our partners which you can see in this table, and they can pull on that content. So we know it's approved. It's scientifically sound. And it's going to be consistent across all of the different projects that we have going on. I'm not going to go into super detail on all of all of these projects, but I'll kind of highlight what we have happening the first 3 rows, you can see, is initium health. It's a public health marketing firm who we've partnered with to create the bulk of the content and do the bulk of the dissemination throughout Colorado. So like, I said, they're translating that toolkit information on the what we know about cannabis and high concentration cannabis into

[33:09] content. So things, like videos, infographics, podcast social media posts. And they're going to push that information out to communities across Colorado through an integrated advertising campaign. And then they are going to have, like, I said, an emphasis on social media to reach those youth populations. I briefly mentioned this before, but we're also putting onto our exhibitions here in the Denver area where I'm located. It's just a different way to educate the public and engage our target audiences on the topic rather than maybe a Psa about high concentration cannabis, just a different way to engage people and get them to think critically about the topic. Next, we are going to have a series of trainings on motivational interviewing that's available to community members which I mentioned. So it's really the the concept of asking open ended questions, reflective listening, so that

[34:09] parents or trusted adults, or a peer, if someone can engage a friend in a conversation, or their child in a conversation about their cannabis use could be specifically high concentration, but generally just helping people have that conversation understand underlying reasons for using it and maybe assessing their openness or willingness to change. We also have a chat, bot, and development, and that is going to be housed on our project website. and the chat bot will allow people who are on the website to ask questions related to high concentration cannabis. and then it will match them with answers that were derived directly from our toolkits. And then the last thing I'll call it. As I mentioned earlier, we're also partnering with the other campuses in the School of public health to really extend the reach of our messages and specifically target that college age population.

[35:11] So throughout all of those projects, I just walk through very quickly. We are, of course, implementing evaluation efforts to really understand the true impact of all of those different projects. And we're largely interested in learning about any changes in knowledge around high concentration cannabis, as well as understanding those related behaviors of cannabis. Use and we'll hopefully be implementing a long term follow up evaluation to see if exposure to our materials changed. That knowledge or their behaviors in the long run. and also the follow Up survey will help us kind of understand what worked well out of all those projects I just walk through. What might we want to double down on in the future. What might we want to adjust going forward?

[36:05] So this is my last slide here for you all. I just wanted to highlight again that we're really trying to educate the public about the harms associated with cannabis use and high concentration cannabis use in those target populations. So youth and pregnant people and we're not only just trying to. We're not trying to scare them, but educate them and also give them tools to use alternative strategies to cope with stress. And then, lastly. I'll just emphasize again that we're incorporating community advisors and community input. Throughout all phases of the project to again ensure that our messages are well received and actually useful, and making an impact in the long run safe. With that we can open for Q&A.

[37:08] Go ahead. Adam. Thank you. So I I guess. One question that I had, and and I had a couple of comments. But I I did want to PIN down this point. in the the report and the the literature that I've reviewed, and the literature that you all are citing. You know, Delta 9 Thc. Is is identified as the the main psycho active molecule in in both flower and these and these cannabis concentrates. And I'm I'm not aware of any evidence that somehow the Delta 9 molecule from a concentrate affects the brain differently than a delta. 9. Molecule from from flower. The issue seems to just be the the strength of the product, the concentration of the the Delta. 9, I mean, I know there's true beans and and minor cannabinoids and other compounds. But it, it doesn't seem like the Delta 9 is somehow affecting the the brain differently from a concentrate

[38:14] primarily just that there's more of it. And I know that's a, you know, unfolding research area. But I just wanted to see if that if if my layperson's understanding is is fitting with the the study and and your review. Yeah. So I I mean, it's a great, a great point. I mean, we've you know the the language, of course, of HB. 1, 3, 1, 7 is sort of what we live within, and there's not a definition per se of high concentration. And we we actually have an infographic. I'm not sure, Colleen, whether you can dig it out real quick. I probably can't where we've tried to grapple with this, because concentration is only one determine of what gets to the brain. And so somebody might use a high concentration product, or they might you get a substantial or, let's say, a dose

[39:02] through edibles or other products. And this is something we have just probably put together, finished off in the last month, because we've struggle with the same same challenge. So there's the question that you posed how much? Tc reaches your brain. And then we try and go through different products. how they are used, and then have some material there on the amount in the different products, you know, generally around range. So it's it, of course, is you're you're exactly right. So the critical thing from the point of view of the effect is how much gets to the cannabinoid receptors, and yes, other things may modify a bit. But here we've tried to. In fact, capture that, and then go along with that, of course, is somebody's use patterns, tolerance and

[40:00] and and so on. So that that is our effort to put together in one infographic, if you will, an explanation. You know, that addresses your, you know. Question. We've we've grappled with from the start of the project. I mean because there's not, and there probably never will be, a concentration definition if you will, for what is, quote high concentration. The that I think, Adam, that answered your question. It. It does. Yeah, thank you. Dr. Sam, Ed, and and you know, colleen, I I did. I guess I had a brief comment I did want to mention. I I appreciate the the concept that you were sharing that You know, this education would not be sort of a fear based curriculum that you know there would be a focus on. On. You know well what causes stress and what are good ways to deal with stress. And who can you talk to? You know, when you're feeling stressed and what are positive ways to deal with, you know, stress anxiety tried to get to some of the root causes of

[41:03] of team cannabis use, because you know, back in the in the eighties, and and some folks on the call probably went through the same curriculum. But you know it was all the the dare program, and it was. It was not a evidence based education. It was a. It was a fear based indoctrination. and you know they would present these really extreme, you know. Well, if you if you smoke cannabis, then the next thing, you know, you know you're gonna be institutionalized, or you'll go right from cannabis to heroin, or whatever the case may be, I mean. But the these are things they literally were. We're telling us back when I was in school. and and the problem is then when you get old enough to try cannabis, and none of those things happen. It's really easy to go. Well, they just lied to me right, and just throw all that information out, you know, because you go. Well, you know that's none of that was true, like they just lied to me. But it but it's tough, because what it didn't give us was sort of a nuanced idea of. You know what substances do, what the trade offs are. You know what the harms really look like

[42:10] and and didn't give us any, you know, coping strategies beyond. Just say no, and in in my opinion that those old fear tactics were were counterproductive. I I frankly think we would have been better off without being exposed to any of that material, because I I feel like it was counterproductive. So I I I really do appreciate that you're talking about. You know this more nuanced message and and helping teams, you know, cope with mental health issues in a in a more broad way. Thank you. Well, you might stop sharing if you get. Oh, okay. Sorry. Actually, I have a question about. Go ahead. I love that so. But but Brian has his hand up first, so. Well, why don't you go ahead, Tom, since it's relevant to what they got on screen. So in follow up to Adam's question and thanks for the question, Adam and I appreciate this infographic and your response.

[43:02] Do you think it's I mean, I'm just wondering I didn't hear from you whether it's the amount of the milligrams of tch, or is it? The the concentration is like, if you overload a system. then you're more likely to have potential. I don't. I'm just, you know, making this up right now, but you know more chance for adverse effects. I guess if you overload the system or pi effects, maybe positive and negative effects, I don't know. Yeah. yeah, I I. So I mean, I think the answer. And let's, I mean, I think a lot of the basis for your question is absent from the literature, and you know we were, of course, searching for that kind of response. I mean, I think our our our clinical toxicologist would say that the in terms of adverse effects, and let's focus there from the moment the risk probably simply just goes up with the amount reaching

[44:04] these receptors. Now, if there's tolerance, then more has to get there to make a to make a difference, and there's to my knowledge. And again, you know, perhaps there's some finer neurosciences going on here in terms of sort of how much has to get there. The higher the degree of receptor activation. What you find with, you know, Meta, with functional MRI Imaging. I'm not sure we've got we. At least we didn't find literature that gets us to the point of particular concentrations, either for adverse or you know the the beneficial effects for which some individuals use cannabis products, and I think, as colleen alluded to. The the underlying message then, in part with the campaign on this campaigns becomes the more the the potentially riskier. And and again, that's the big change, of course, in the marketplace is that there are higher.

[45:08] higher concentration products. And of course. flower, you know, again, going back to 60 70 s. With 3 or 4% Thc to the current marketplace, which is 20% good. Quite different. Doses of Thc are reaching the brain, comparing now to then. Okay, I'll let Brian go. But I'm gonna come back. I got more questions about concentration. Thank you. Yeah, thank you all for the work that you're doing in reviewing this literature, and for coming and presenting it, sharing it work you're doing both on the research and the outreach with us my question centers on. I guess, like within the scope of what you've been tasked with. You've been focusing on what we would call Delta 9 Thc. But I wondered, in the course of your research.

[46:01] you have any recommendations or have you encountered any research surrounding other kinds of adjacent compounds like Delta 8. Or I think there's the other compounds like Hhc. And Tco. That maybe have similar kinds of effects. But by the letter of the law, are regulated in different kinds of ways. And so my high level question is just like to what effect should the scope of the ways that we think about policy making and regulation be broadened to encompass these other kinds of? And I'm not a chemist or Pharmacologists like understand this, but like these other kinds of compounds that appear to sort of act in similar kinds of ways? Or how should we think about regulating in this kind of way. So I'll give you a hey? Probably I'll I'll I'll warn you. I'm gonna give you an unsatisfactory answer. But I mean, we've been focused by by what we've been told to do on. You know, Delta 9 Thc. Recognize them. Of course there are many other cannabinoids. I mean.

[47:04] you know. Lots of them, I think, is my understanding so. And you know, in in some places they're certainly becoming. you know, wide, more widely available. And the regulatory approaches probably are far more nascent right now for those agents than for the cannabis and and Delta 9 thc. So I I think right now from from our project. We don't have anything really specific underway. I mean part of the the challenge. When we started the Literature review just sticking with you know, cannabis and Delta 9. We we had a 60,000 articles in our initial screening, and the update, you know, for last year was 6,000 and you know, as I mentioned, from the original screening of about 60,000 articles.

[48:02] we identified 452 that met our criteria, and which from which we extracted information in the last year from the 6,000 we extracted we have identified a hundred 52 from which we'll extract data which suggests that, you know, there's more and more literature become relevant, I'm sure if we begin the to screen on all the other cannabinoids that we would probably find a a growing literature. Part of our challenge is simply the effort to plow through all these references is enormous. But I I'm I'm sure as the product marketplace widens and interest grows in these compounds in their use. Reviews like ours will be taken on whether we'll be doing it or not. I don't. I don't know. But we we had to restrict for feasibility. Sure I understand. Thank you. Robin. You're you're all set right.

[49:00] I'll let Robin go, and then I get more questions. But I'll share. Share the pay. Okay, maybe we can go around a little bit because I have. I have a couple as well. But the first thing I wanna say is how much I appreciate the work that you guys have done. And I like the emergence of the and I'm a I let me just say, I'm a parent with lived experience of of de downsides of marijuana use. And what I've come to believe over about 5 years working on this is that a lot of people use these products without any problems at all. And some people use these products with devastating consequences. And so for me, I'm always looking for. How do we communicate that message without doing what Adam talked about, but to give people real tools and information so that they can avoid some of these things. I have a niece right now whose son has just had his first episode of psychosis. His father is institutionalized right now for a very serious bipolar disorder with psychosis.

[50:05] And talking to her, I realized how little people understand about that relationship. So I I didn't mean to make a speech. I wanted to ask a question which is in your group of youth, the target population, do you, or have you thought about a subgroup people who have genetic predisposition to schizophrenia or other serious mental illnesses, because there is a real urgency for parents to understand that if your kid has a first episode of psychosis, and they have a family history of genetic problems. There is a possibility that those things make each other worse. So that would be my first question. And then I also wanted to know how much money you guys have

[51:00] and how long you'll be working on this. Thank you. Yeah, so, Colin, I'll I'll take on the second, which is easy, and I'll I'll take on the first as a prelude to you. The the answer on funding is, you know, public and and you know, available. So this year we actually have 3 million dollars to expand and that has gone. I mean, these literature reviews are quite expensive in terms of building the team to do that. But this year we are directing about 2 million dollars towards the campaigns that Colin described and we await the sort of the legislative direction on where things will go for next year with your first point, and we we certainly understand the the. the concern I mentioned that we are doing a systematic review on Mental Health and cannabis use.

[52:03] And in our initial this broad scoping review. the one area where we did identify enough scientific papers to pursue a full in-depth review was cannabis use and mental health. for example, and I can't remember the count. There are a number of studies on cannabis use in first episode of psychosis. and those will be reviewed. There are, you know, studies on exacerbation of mental health status and cannabis use. There's also a literature on potentially beneficial consequences of cannabis use for those with mental health disorders. So we are systematically reviewing all that. And I guess you know I sort of lamented the state of the literature in general. And this is one of those areas where at least there's enough

[53:01] that we're going to, that we are in the process of bringing all the evidence together, and that that's a review that we anticipate completing, you know well, with a report. Oh, I hate to. I'll I'll be vague, but it's certainly in the matter of the next months and not, and not so far out. And but, Helen, please. Yeah, I I would to directly answer your question. We haven't called that out specific subgroup, but we are highlighting that throughout our materials. So like, I said, in the toolkits there is specific attention to what are the physical and mental health impacts of high concentration cannabis use for youth and then pregnant people. But in the youth that's really the the main area that the scoping review, like John said, did call out evidence that can. That we can say is, is different with high concentration, cannabis, and in all of our workshops that is the piece that youth really attach to as well the the fact that if they are predisposed to having schizophrenia or other mental illnesses, that.

[54:07] using cannabis or high concentration, cannabis could make that worse, or make the onset earlier. That is, they really attach to that. So we're looking to highlight that throughout our materials, the videos, the infographics, things like that. And the video. Specifically, we're also going for more like documentary style, like using stories, live stories from youth. In Colorado, who have experience with different negative impacts. And that is definitely one of them. So I appreciate the comment. And your story. It's we've we've heard so many different versions of it. And you're right. So many people don't know about it. So we're definitely looking to pull that piece out. Thank you so much. Tom, do you want to go ahead.

[55:00] Yeah, Jonathan, and Colleen. Again. Thanks again. I'm just wondering if there was discussion. You know, when you're taking a precautionary approach Sigh Slide that I wasn't familiar with the wings spread. I know that's a place in Wisconsin, but I don't know if that's where the conference was held. But right. Well, it must have been. It's certainly named after the place where the conference was held, and this is sort of, you know, enumerated in regard to sort of environmental agents. Original, I mean the precautionary principal, of course, is. you know, well known and. Yeah. And and certainly seems seemed applicable to us here. Well. So in the, in the flavor of taking a precautionary approach. I was wondering if you or you know, especially we in Colorado. should have gone the way. I I know Vermont. I I missed the slide. I wanted to see the slide, but it went off the screen so fast. I thought there was a slide that may have different states and different rules.

[56:08] Yeah, we'll we'll get the report to and be happy to provide you with the the original report from the National Conference on State Legislatures, as well. But the you know, the the gist of Vermont's law is that nothing greater than 60% is. But. And I wonder if there was ever any discussion about doing that in Colorado, because that's a precautionary approach. Right? Yeah. And and in fact, I mean, we. we looked at the where the 60% came from. And of course that Vermont can't PIN that through any particular paper or study. I I mean again, my understanding of the origins of the work we're doing. It was came when The folks particularly concerned, and you know, are now representative and pediatriciana. Carlisle was one of those concerned realize that there just was not going to be the literature that will allow them to anchor concentration

[57:06] limit. So you know, I mean that it's being, you know, precautionary. I mean, there's certainly products like, you know, solutions and vape pens that deliver higher than 60% on the in the marketplace in Colorado. So the kind of a side or a tangential question is, you know, evidence suggests the human brain is not fully developed until the age of 25 and everything's, you know, we still have these 21 rules which may not be based in science either. Right. So. Right? Yeah, we we had some internal discussion about, in fact, age 25, I mean, you know, same issue. I've been heavily involved in the tobacco, and it's consequences. And you know this. Th. There is evidence. Have reviewed this multiple times in the Surgeon General's reports that nicotine affects the adolescent brain and and lasting

[58:01] ways. I think the question came up around. could a 25 year age limit be implemented for some products, not for others, or you know whatever. And and we have did not find any evidence specifically conclusive enough, I guess, to include that in the report. Okay. Brian. Yeah, thank you, Tom. I appreciate it's a nice all you there like I was gonna ask along the similar lines that our board undertook something like an 18 month process to come up with a set of recommendations to our city council governing social consumption, and as a part of those recommendations. We suggested that we not approve high concentration products to be available, and social consumption lounges. hospitality businesses. This issue of whether or not 21 versus 25, we ultimately made a recommendation to council again, that, like a 25, and up be the limit for a social consumption lounge

[59:05] that much to the screen of many other stakeholders in our community. Again, that's not our decision to make. It's councils. I recognize that. But I wondered that, like for us as a board if you had any. Themes, topics, priorities that you think that we should be considering as we weigh major policy decisions around social consumption. around, reviewing or providing oversight or guidance for other kinds of public health interventions. For youth! for to some extent, like approving new licenses and citing and density. In all of your research are coming across these papers again, recognizing that you were narrowly scoped on concentration. Are there things that we should be like weighing or prioritizing around things about licensing youth use, or other kinds of matters like that.

[60:00] Well, that's a a broad set of tough questions. I think you know, without without ducking and with bobbing too much here. I would say that the you know, from the Hi high concern public health wise, I mean again going back to what colleen emphasized gestation and breastfeeding critical critical window, and, you know, bringing awareness to those providing healthcare in contact with those who are pregnant or or breastfeeding, we think, is is a critical moment. Now how that relates to social use. I mean, if you think about how patterns of acceptability of alcohol use during pregnancy change, I mean, in a way we need to have the same depth of knowledge reach the public at large, and particularly those who are likely to have

[61:04] children. I you know, I think the other concern. I think this does go back to our discussion about the adolescent brain and and and the fact that substances may have lasting consequences. I think that is an area. How you can deal with that. I mean, if you think about what might be restricted in social lounges. That's such a small portion of the opportunity for young people to use high concentration products. And I think that's you know where education has to. has to has to fit in. I mean, I you know, I think, And how we achieve that broad reach is not, you know, it's something that we are working on, and the way I would see our educational campaigns working, I mean, assuming this is an ongoing activity, the school of public health is that we would continue to

[62:03] direct and redirect as we learn more. and as we learn, more colleen mentioned evaluation, I mean, I I think part of what we need to do is understand if we are getting to the, you know, 1516, 17 year olds, whomever who may be using a vapein, or dabbing and getting a high high dose. So I think we need a multi-pronged approach. I mean, I think our education campaign as part of that, you know, we looking for these ways to try and. you know, broaden our broaden, our reaching, or, for example, reaching to critical health care of those new healthcare sector who may interact with these particularly high risk. individuals. But I you know, I think our discussion, your comments, highlights. the fact that we need to reach sort of everybody. And that's parents. And that's children that's adolescents. It's young adults and those high risk groups. And we're trying to do

[63:04] trying to do both. And this is our first year of sort of a high volume educational campaign, and we'll we'll learn a lot. Yeah, thank you so much. I'm assuming part of the process will be to study the effects of this educational campaign. Yeah, calling that go far away. Yes, yes, definitely. Not only are we gonna have evaluation efforts for the public to use and after their exposure to the materials, but also for our partners understanding the process, how it went, what went. Well, things like that. So we're we're doing all the evaluation. You know, we we love the data. Adam. Thank you. Yeah, just, I wanted to comment briefly, as as we. you know, talk about policy recommendations that that this Board might

[64:03] consider, or or that might be considered at the State level. And and this isn't intended to be unduly critical of of the authors of the report, because I understand you all were. We're given a task by the State legislature, and you know part of the task was making recommendations, and you followed the you know the guidance and and requirements that the legislature provided. But as as we do get into talking about policy potentially, I just want to point out. I think everyone understands this, that you know. Truly, we live in a world of trade offs, and I don't believe that realistically, it's just are people using cannabis, or are they sober? It's more that, you know, people feel a certain way, and they wanna feel different. And you know, so so to some degree. It's, you know. Are they using cannabis or something else? And so, you know, I would just and I we'll, we'll provide a couple of articles to to this group, and they're probably articles that you know, Colleen and and Dr. Sammut that you all have seen. But I'll email them to you also. But.

[65:10] But. You know there, there is some good evidence that in States with legal cannabis, you know. Rates of alcohol abuse can be lower rates of opiate abuse spin. So diazepine abuse can be lower. And so there is some evidence of people substitute substituting cannabis for substances that really might have worse public health consequences, and and my other concern, I guess generally about restricting access to a legal, regulated, tested product would be pushing people towards the illicit market, and and I think part of why the illicit market is has really shrunken in Colorado is that folks can get, you know, high quality regulated tested products that are inexpensive. So why would you go to the illicit market? And you know I would also have a and and I know the these aren't the recommendations necessarily of the authors. But

[66:12] you know, I I would see a trade off potentially there. That if the regulated market is is not giving consumers the products they want. I'm talking about adults. Naturally, the products they wanted, the prices that they think are fair. Then more people will start looking at the the illicit market, which you know could have have worse health outcomes, or, or, you know, potentially, empoweres. There's. you know it's it's illicit for a reason. But you know I I know that the authors are aware of those trade offs. That was something more that I was just pointing out for for this Board to to keep in mind as we talk about policy. You know, just a couple of quick comments. I mean our sort of public health jargon for this would be overall public health impact, you know, taking into account sort of everything. And you know, this same discussion comes up

[67:01] right now in a pretty hot discussion about electronic cigarettes and public health impact, and whether those smokers who switch gain some health benefits, you know. while the access to these products may, you know, affect youth initiation nicotine addiction. I mean, I I mean, I guess the other thing that we'll all watch with interest is what happens with the classification of cannabis by FDA, which you know again we'll see where that goes. I it's in schedule one, of course, for a long, long time, and we'll see. It seems that there's a move to reconsider that. I can tell you that right now. doing research on cannabis is problematic for those who want to use it experimentally or administered because they are left. They're funded by the National Institutes of Health with using these experimental cannabis. that that is, that is available. And I think now the flower was at 3%.

[68:01] And I think it's going up to 6%. They're working on some model other of other ways to to use it. But that's certainly been a barrier to during doing research is relevant to the marketplace. Other questions. Hey? Anything from Michigan and Jacques? You got your hand. Yeah. Just have a slight question. Comment on the aspect of the youth. In regards to finding ways to cope with stress. I believe you were talking about have you guys taken to account just like social factors and kids just kinda like being kids to rebel and like finding like, including that as not as like not just kids like we're doing this to cope with stress. Because I mean, it's not the whole story.

[69:04] Yeah, that's fair. I think there's a host of reasons why somebody might turn to it, especially youth. But also it's not our only population. But within youth, specifically. we are focusing on the stress root cause. I think peer pressure is another thing. We are accounting for that in like our chat bot, for example, and other materials of like the motivational interviewing trainings like, what might you say to cut back your use, or what might you say to stop using? Or what might you say to someone who offers it to you? So kind of that peer pressure aspect? But focusing on the stress more heavily as as a root cause for both of our target populations. Pregnancy. One idea I I was just thinking of of. If

[70:04] Boulder City Council actually ever did decide to take up our recommendations on hospitality establishments. and this is like totally magical thinking. You know. Decide to go with our recommendations and and try the the age limitation of 25 rather than 25 or 21. It would be an interesting testing ground. Now, I know, as you said, both you and Brian kind of said, it's a limited scenario in terms of where people can. You know, people can get their concentrates anywhere. They're not necessarily going to go to a hospitality lounge, but it would be an interesting scenario or interesting research designed to compare that versus another community that had hospitality and suites, and what the effect might have been if that limitation went through.

[71:01] I guess I'm trying to intrigue you. I agree. I mean, these are the kinds of scenarios that we should take advantage of, too. Look at, look at the consequences, and you know people do. Of course, these kinds of analyses very often at the national scale. If the data are available. Okay. other, any other questions. I can actually. This! Oh, sorry, Kate, go ahead! Okay. Good. I you know I I'm just trying to, you know, absorb all of it right? I think there's a lot of information here. I think the report itself has a lot of good things. I obviously wanna thank you both for coming today to present and you know, I obviously, not obviously. But I wanna look more at it. Just because I'm curious. Just wanna just appreciate the work that you all have done, and and glad that that somebody was put forth to do it right. And I mean, there's a lot that still needs to be done from a research perspective. And you know the the caveat with like, you know, it being schedule one and not being able to do the right research. And now, you know, with the possibility of rescheduling more research can be done by different organizations with different products. And so yeah, I think there's some some potential, you know, growth with the resources that are out there

[72:15] out there which is in my mind. Really helpful to to think about. You know. I I I don't think there's anything specifically. You know, I'm interested to see the tool kits and resources as somebody who, you know, like knows other mental health providers that are looking for that resources, those resources. I know medical providers that are looking for resources to give to people. You know, teachers and parents alike. So you know, just really excited to see what what you all can put out, and and what that looks like I do also think you know, in terms of the you know Robin's point about kind of like resources and real tools with the nuance. Right? I, I I I keep going back to this idea of like, you know. Yes, the psychosis and schizophrenia, but also this kid that that has to use it for seizure, seizures, or pain, or who is using that and hasn't found anything else? How do you make them feel validated and not feel put out because this new campaign is doing this, and I don't. And again, not to say that it shouldn't be done, because there are, you know, the nuances on both sides.

[73:17] but making sure that that whatever the choices that are made again, that nuanced approach of it's good for some things and not for others. It's not for your good developing brain, but it's good for this, this thing that affects your brain, that causes seizure, you know. So all the things in in that. Go on so. Not a not a question here just more, you know. This is this is what I've been reflecting on, and kind of thinking about as we're talking, and just really grateful for the conversation, and excited for it to continue, and to for us to to see all again in a in, however long. To talk about it again. Yeah, it's a lot to balance a lot of lot of different perspectives. We do have the benefits. Including like seizure disorders in there. We emphasize, obviously talking to your doctor, and it's only for specific medical conditions. But yeah, it is a lot a lot to balance. There's so many different scenarios. So we're doing our best.

[74:11] No, well, thank you. I I just wanted to ask, and and if there's you know, literature, we should read, or or something. you know, cause this may not be a a quick answer. Anyway, the the question basically is, you know. So we're when we're talking about the way the brain tends to develop between the ages of 21 and 25, and and how it's developing and and changing. You know, I'm gonna make an assumption that if you look at the 4 year period between 21 and 25, the changes are less dramatic than between the ages of of 2 and 6 say so how, how do you quantify, or is it even possible to quantify, how much the brain is changing and developing? And if it's possible to quantify that, then, between the ages of 21 and 25,

[75:05] how much is it changing and and developing? And I I realize that sounds like a simple question that may have a totally not simple answer at all. Well, I'm gonna I'm going to say I would have to talk to somebody more knowledgeable than I am, and I suspect Colleen is going to take the same tacked and we could look at. I mean, I I still remember I have when when prior position, that we had a childhood neuroscientist I worked with, and he would talk about brain development, and it would snap his fingers. And it would say, for the newborn, that was 10,000 connections in the brain. During that, you know, tiny increment of time. So obviously, a lot's going on early, and it's got to slow down. But I I understand the rationale for your question. I just can't give you an answer, and we'll we'll we'll see we can give, do a little homework and help out.

[76:03] and we will just a couple of other comments. We'll get the slides to you through Kristen. The meeting we're doing on May fifteenth. is available. I mean, if you want to sign up, there'll be a review of basic pharmacology. There'll be discussions of our work. There'll be discussions oriented pediatric health care providers, and you could join that, I think, without difficulty. If you have problems, let me know, and we'll make sure you can get involved in that again. It's on our website and we'll we'll get slides to you right away. So you have the QR code for the meeting. So yes. As with staff procedure for cloud. Once we do get a presentation at a meeting that does go in the next month's meeting packet. so you guys won't receive that until June.

[77:02] However, you did say it was available on your your website. Available on the website. I tried. I looked through the website, and I could not easily find it. It was the. Yeah. Do you want to put that slide back up? Just put the. Yeah, I can. Also. Yeah, our code. Put the link in the chat. I'm sorry. Can only be used. I'm sorry. Chat can only be used for technical issues. It can't go out as a group tick group chat. And we will. We'll have the QR. Code up. If you have, if you have I just wanted to say, Chair, that in this month's packet there are 3 links under at the very end, and that one is to the website. One is to the presentation, not exactly this presentation. But you guys's presentation on the communications that you're doing. And the third is to that may fifteenth.

[78:00] Oh, okay, I see that. Yeah. Numbers. You have those 3 links. I see that right? Am I mute? No, I'm not mute. Okay. found it that. Okay. Is there in person and virtual. Yeah, we're doing it in person and But you know, you can register virtually. Okay? Alright. Any other questions. Okay? Well, a collective. Thank you again. And we look forward to continue working with you. Okay, great. Thank you. Thanks for the opportunity to speak with you. Thank you. Thank you. Bye, all. Okay? So somewhere, I have the agenda

[79:00] matters from a city attorney. Good afternoon, everyone, nothing from your city attorney. Hey. regulatory Licensing Office. Certainly as per request from the board. You have both the link for the sales tax revenue report web page for the city and the list of currently licensed cannabis businesses. As to recruitment, we did not receive any applications during this last recruitment cycle that ended in April nineteenth there was not a planned midyear recruitment at this time, however, now that we have 2 vacancies with Member Christy's resignation, I have circled back with board, recruitment staff and waiting to hear back if anything else can be done during this time.

[80:01] So with that in mind, it is really important with us, having such a a smaller board that we do have attendance for quorums. So if you know you're not going to be available for a board meeting that you let me know as soon as possible in case we need to make alternate arrangements. Please. So in light of that, or in the spirit of that, I'm out of the country the next meeting. and it's gonna be up for me to get on. So that would leave us with Member noble Member Keegan and Member Foster. So that is not a quorum. But maybe Member Green. Well, maybe Member Green, that is true, that is true apologies. I was looking at my screen. Yeah. So. Yeah. figured out. If you would just send me an email reminder. Sherkinsman, that would be great. No.

[81:00] what are the, you know? So 2 board seats are supposed to be for industry members. What are the just No member. Foster is an industry member. Right? No means. Yes, Member Foster, and then there's a vacant seat for the other. So we have an at large. and another I'd have to look. I'm sorry I don't have that report pulled up, but I know it's it's cause. Remember, Christy was an at large, and I believe it's one more. I think you have that right. I think it's an industry seat is open, and that large seat is open. I think you have that right right. Well, I was asked a question. and I don't know the answer to the question. I guess I could have them ask you where? Okay. you know. So we're not supposed to name names according to 2 lawyers ago. But there was a certain establishment in Boulder that hoped to be the first cannabis lounge probably will not be at this point time.

[82:03] But would a cannabis, a potential cannabis lounge, be a an industry represent? Or could they be an industry representative. I'm going to leave that answer to our city attorney's office, Mr. Ramirez. Just wanted to get him out of, you know. I wanted to see his his shining face. Alright, thanks. Okay. So it is an individual that at this time does not own a cannabis. license or business. And so these would be retail, or for the most part retail and medical. or grows. Yeah, no, I mean, if they do not own a license, or actually, I'm gonna double check. But I will get you the answer this week.

[83:03] Okay? And then again, even if they live in the city of Boulder, but their business is registered elsewhere. That does not qualify them as best you know. Find out! Okay. Alright. Thank you. Okay, just quick. Sorry just for Kristen. You had one more item. I just wanted to make sure you didn't skip over, and just. Oh no! Board. Members. Early. Sorry. Okay. Go ahead. The last item for matters from the Regulatory License Office is future meeting agenda items you would like for me to record. Is there anything you would like to add to the existing list? I know we had some items for June that were in in the works, but

[84:02] Member noble. I'm just wondered, and I I don't. This doesn't feel imminent, but or high level of urgency necessarily for our board. But Adam mentioned a couple of things around the impact of, I think what you were saying, Adam, correct me if I'm wrong, please, but that cannabis has had a positive impact on opioid addiction, I think, in places and also on the illicit market, and forgive me because I only have very lay understanding. But I understood that Colorado had more opioid deaths last year than ever before. And I also read a couple of articles around cartel activity again. Very lay perspective. But if you wanted to bring more information on that to the degree the Board thought there was anything actionable we could do. I would be interested in learning more.

[85:05] Yeah, thanks, thanks so much. And I did. emailed to Kristen a couple of links. that I'd like to include in the in the new packet, and and one of the studies does talk about opioid use. And I've come across a couple of other ones, and I'll I'll see within the next few days if I could grab a couple more, because they're they. They fill in some different pieces. But I I do have at least one link that I want to attach that that should speak to that question for the the next meeting. Where Jack. Yeah, one thing in the increase in opioid deaths. Is more related to the Fentanyl epidemic taking over, because if you look at when cannabis was first legalized in Colorado. Opioid use dropped drastically. I don't have the the graph. I'm sure I could find it if I looked for it, but there is a graph of that, and then

[86:17] I'm sure that's gone up with the increase in Fentanyl usage. And then, in regards to the cartel, the cartel actually can get precursor chemicals. From China. There's different manufacturers in China that will send that to the cartel, so it's easier for them to get access to. I've seen a couple of different articles on this, and I I think the cartel is is really more involved in producing the funnel and and then distributing that, instead of, you know, getting pills like from pharmaceuticals. So I think there's a little bit of a difference in the opiates. Thank you, Jock and I. I don't mean to suggest that cannabis is causing either of these 2 problems to be worse. I just heard Adam talk about the potential benefits, and I just wondered if there was something more there. Thank you.

[87:07] Certainly, and as that the deadline for packet materials is Monday, May twentieth, for the June packet. Eric? And did, Brian, you have any questions about the list, Brian? Oh, I just wanted to bring something up, but I don't mean to step on Staff's toes, but I think that staff had just expressed a concern that like we just wanna make sure that we get folks here into the meeting on time to give staff enough time to get everyone set up and like the configurations right? So we can start on time, since it's a non-trivial kind of just technical tasks of just getting names and panels and all that kind of stuff set up. So just on behalf of staff. I apologize if I'm stepping over something intended to say, or you want to say it differently, that, like.

[88:00] Fine, like. We show up early for meetings so that we can get like staff and get everything set up, and we can start on time. Yes. So there's multiple steps. It's not just like we flip a switch. There's multiple steps that we have to do for renaming pro, promoting to panelists. giving permissions. And that does take time. Especially when it's just one of us staff members. That's running the meeting. So you know, if you could make sure that you're in the meeting room, you know, even 5 min earlier that would really help Staff out. And so we're not a scramble, because these meetings do start at 3. Is, is 2 55, a good good kind of rule of thumb. Great. Okay. It also gives you a chance in case your zoom do does what mine did the other day for a separate meeting, and decides to update right as you're trying to log in. So it does give you a little bit of wiggle room. There. Thank you. Vice chair. Keegan. does this board have anything else for licensing.

[89:01] Well did we wanna address any more of the items on the list, or add to the list. I'm sorry people had stopped raising their hands so. What was the idea for the cannabis. Oh, sure, yeah, I was gonna bring up. But so in my members from matters from members, excuse me. Matters from members I had brought up these 2 links to a daily camera article in the westward article, both referencing the Cannabis Club at Cu. So they've hosted job fairs, and they do other kinds of events on campus. So I would like to invite representatives from the cannabis to come speak to our board, either on the kinds of efforts that they are doing on campus as well as their experiences as young people around cannabis and space. I think, would all be really valuable insights for our board. So Ldr. We invite canvas for future meeting.

[90:00] Okay. Do you have an idea of what that scheduling might look like? Vice Chair Keegan, as Sunday? Or is graduation. I imagine it probably won't be until the fall, so I'd say September, October, and I will back Channel with them and find out who their new leadership is, since I think the founding members are graduating here on Friday or Sunday. Perfect. Yeah, if you could just get me that information, I'll just make a note on on the list. Fall 2,024. Thank you. Tom. When's the last time we had cinnamon bid? Well. how long. Within a year or more. Yeah. shift. Cause. She's she's working on a number of new projects which are kind of interesting, including a breathalyzer test for Thc. that's far from you know it, it still being researched so. I mean, is this a good moment just to talk about? Since we're in May, and looking into the summer about folks availability, do we wanna skip a meeting? And

[91:07] June, July and or August, just recognizing as a summer. And people are at a different tempo. So both on the topic of like future meetings. Also, maybe future not meetings are there? Is there a month or meeting? We'd like to skip and give Staff that time back? Well. and so. The June meeting is gonna be the third of June. July meeting would be the monday, July first. That is a holiday week, the holiday being on the fourth. and then, of course, August would just be August Monday, August fifth. 8. Just for reference. Yeah, I I was gonna say, I was looking at the calendar earlier today and I I won't be able to make the July meeting. Not that I'm you know, obviously a board member. But just to say that like, I think you know, if we were gonna pick one

[92:06] seems like that. One probably would be a good one for for all folks, but I just wanted to put it out there. I'm in the same boat as Kate. I will not make July. Me me 3 I I have a clash with the July meeting, so I I do think maybe that would be a good one to either skip or or reschedule, if possible. Alright, hearing all that I would recommend. We skip the July meetings there motion, or that's just a sense of the board. I I I would so move. So I don't know if we need to do. We need to have a motion, Roberto. getting them off camera again. No sir, no motion, needed. Oh, awesome! You! You also gave like the quickest presentation ever which I truly respect. When you, when you have the city attorneys portion that was that was right on.

[93:04] Okay? In that case, let's go on officially to the last item on the agenda. Brian, did you want to do some other things first, or do you wanna go and. So I think it maybe just like builds on items for future meetings, so that I think a topic for a future meeting. Again, not knowing the exact scheduling for this would just be recognizing that on April thirtieth the Dea did release guidance, indicating they're going to reschedule at a Federal level marijuana as they define it from schedule one to potentially schedule 3, and that might have. some little or no implications for the regulated businesses and industries that our board overseas And so I just wanted to include some future Ma materials in the future reading packet potentially set up a time for us as a board to discuss as like. There's more clarity around this policy. Change

[94:07] what? Where this is, gonna show up for our regulated folks, and so I would just welcome feedback from the board about. And then the context of a discussion about the Ea rescheduling marijuana as they defined it to schedule 3 from schedule, one like what would be other stakeholders, or a conversation that would be helpful for us as a board for our city council and for our community. To sort of grapple with this pretty significant change. I guess my question is like, what questions do you have, or what would be helpful for us to scaffold the discussion around on this matter? Who should we be talking to? What's the timeline if it goes forward. Think that this is just in this kind of public comment phase again, at like a Federal level before the the Ea makes a formal determination or recommendation to change that. Again, I haven't read this that closely, but for the June packet I'll include materials as best as I can find. I know there's a Congressional Research Service memo that just came out June thirtieth that I found really helpful as really focus on the legal aspects. But I think

[95:23] on the regulation compliance pieces I would like welcome ideas about what else we could include that might change. So No. 2 E. 2 ades can be a huge thing for a lot of folks. I would welcome other ideas about like how we could scaffold the discussion around schedule, the rescheduling. Alright Adam. Thanks. So the the biggest impact assuming this gets done and and is finalized would be on 2 80 e, and essentially what that would would mean is on the store side that cannabis stores would be able to take the normal and customary business deductions of other retail businesses which are currently denied to them.

[96:10] Because cannabis, or because marijuana is a schedule, one controlled substance. So the big practical effect is is tax relief. At the state and local level to me. There's not. And and that doesn't mean that that we wouldn't want to recommend anything. But there's no change that's so obvious that that I'd go. Okay. Well, we have to deal deal with. You know, this new changes as part of Collab. The immediate effects going to be tax relief, which which will be good for the industry. My understanding, I think this is accurate. is, I believe, the Dea did follow the recommendation. To reschedule, to schedule 3. But that now we go into this notice and comment period, where they you know, publish in the Federal Register a proposed rule that would be the rescheduling rule. Members of the con. The public get to comment pro and con

[97:09] and then they publish a a final rule, and I I don't know the exact timeframe, but that'll take. you know, a few months at least. So I I believe we may see that rescheduling be finalized this year. But it's gonna take a few months. It could totally go off the rails and not happen. But at this point it seems very likely that it that it will get approved. I have a question. and you might be able to answer it, Adam. So it's a rulemaking. There's not a Congressional action that has to take place for the rescheduling. Yeah, that that is right in this in this instance. Now, you know, Congress would have the power to to obviously pass a new law to des schedule it entirely. But in terms of this process you're that's spot on. This is an administrative rule making process that that's happening at the agency level.

[98:11] Has anyone had any interactions with? You know there's a regional da offices in Centennial. Does anybody have any reason to have any interaction with them. I wouldn't. I mean. I can reach out and see if they happen to have a local expert, but would have any information that might be helpful to us at some point in time. How's that, Tom? Can't answer. Hand it. Oh, go ahead! Kate! Yeah, well, I I don't. Wanna, you know, stop the flow. I mean, I think that reaching out to them would be great to see if they have anything that they'd be willing to to discuss. I think I mean, there's a lot out there about the different way, like the timing on this. And what's gonna happen? And

[99:01] obviously, it's not overnight. So nothing changes immediately. And it's gonna take time. And then there's probably gonna be litigation on both sides. You know. So there's gonna be a lot of that. I think there's you know. Vicente or Cedarburg, or Vicente Lc, did a great webinar last Friday? Kind of going over a bunch of the components of it, and what it doesn't doesn't change, and what it's gonna look like and and what it could look like, and what could possibly happen? And there's just a lot, you know, bouncing around. If I do get that that recording, I'll be happy to to share it with the board. If I get it, because I did listen to it. And I watched it. And they do a great job of kind of balancing expectations because they have multiple levels of of clients. so you know, happy to pro provide that to. But to Brian's question, I think that, you know, like there's definitely a need for us to educate ourselves to a certain degree. But we we also have to be. you know, kind of cautious about what materials we're looking at. And I don't think that this port is ready to have a conversation right on on what the impacts could be. I think that it's about finding good resources at this point and sharing it and then continuing the conversation.

[100:10] So I would encourage everybody to kind of look. Look out, you know, like, do some research over the next couple of weeks, and if they find something that was valuable to them, or provided a good perspective to share it. In terms of, you know, for the next packet next meeting packet for June. But I I you know I would obviously be pretty selective about what you choose, because there's a lot out there. But I plan on definitely finding something to share. And hopefully, I can get the the video link for the Vicente one. Usually they put that on their website. But I would. Yeah, it's up on their website. Kate. It already is from Friday. The front. Yeah. There it yet. Yeah, I mean, I thought that was they did a great job. So they do some great updates, on new rules and and regulation. So anyway, yeah, that's I mean just that. I think we should continue the conversation, and maybe to put it on the list of topics for the future, and just put rescheduling or Federal Federal legislation. And then.

[101:08] you know, rescheduling in on that as a topic, an ongoing topic that we need to kind of reflect on or or touch base on. That'd be nice. Thanks again. I guess I was just thinking of getting on their radar. Go ahead, Brian. Yeah, thanks. I just gonna move on to the new topics. I didn't wanna shift our thread. If other folks had other things they wanted to say the other topics you wanted to add, and this is just the question the staff had already sort of raised it to them. Is that just making sure that we could like update the description of cloud on the city website and just wanted to ask if there's any updates or input that we could provide a lot of the way that the Cloud is described on the city website uses future tenses when we've been working for 4 years. So just wanted to make sure that this the staff is done a great job keeping the membership up to date. But I just wanna make sure that the

[102:01] reflection of all the other kinds of work is updated as well. And if there's any input or advice we could give on that. Thank you, Brian. So for the city website, anything that we put up there has to be approved by our communications department as well. So if you have some proposed drafts that you would like to send over for everybody to look at, we could include that in a packet. And then if you guys narrow it down to to one we would be happy to present that to our communications department because they do have final approval. Right? They don't. They don't ordinarily write the script. They take information from others, and then. So when we want to put something up on the web we, unless it's like an official like emergency statement or an official statement that usually comes from staff as can you please review this, and to see if this is acceptable, and they'll go ahead and review it and and make changes or omissions, or you know, package it. Per the boulder.

[103:13] Communications Department requirements. But we would happy to be to put something in front of them. If Cloud comes up with something. Also, we are under currently undergoing our the website accessibility project due to the legislation that requires the website, updates for accessibility. That comes in July. So we staff are doing a lot behind the scenes working on websites. So if you're gonna do something now would probably be the time. Thank you. Okay, so let's talk about this letter or this email. Anna is in the room. But she chose not to

[104:01] correct. Speak during public comment. So if sorry, Anna, if you were hoping to talk now, it's unless the board decides that they want to get some input, from Anna. Hopefully. Everybody's read it it it's a. you know, describes a tragedy kind of for a 15 year old, and I'll I'll admit that I I've had conversations with Anna. and then yesterday Anna and 3 other concerned parents met virtually with Mayor Aaron, and I was invited to join that meeting. and so there's some discussion occurring at another level, I guess. But does everybody have a gist of what the what the letter describes? I mean, basically, you know. not just this person's team. But you know the report is that many teams have easy access

[105:00] to Thc to concentrate. So you might have seen the photo which was all confiscated from underneath the a teenager's bed and and so I guess I wish Cannabis Enforcement officer was here, because I just wonder when reports are made. I mean, I guess one problem is, the route is not a dispensary. That is correct. The route has a city of boulder and a state of Colorado tobacco retailer, license. Well for the city of Boulder. It's a tobacco. Esd retailer license, Esd being electronic smoking device. But I can per her comments that she provided to me and information that I do know that. There are ongoing joint investigations for the allegations. and there has been.

[106:01] Okay? And would the same be true for any parent of a child or adolescent. Correct if they bring it to us. either to our cannabis enforcement officer directly or to city licensing. We then pass that on, and then it works its way up. And what would. What if if? Let's just say hypothetically. the investigation finds something was done wrong. What's the outcome of that. So for both tobacco and our marijuana businesses there are penalty guidelines and penalty schedules that range from finds to finds and suspensions all the way clear up into revocation. If if warranted, but that is that revocation is a lengthy process. And then one of the parents yesterday said, I didn't get a chance to look this up in the past 24 h, but Delta 8 thc. Is not allowed

[107:07] in Colorado. So there are. Some things going on regarding the the Delta. 8. Yes, and Pam can elaborate a little bit more than that when we get reports of that, we pass that on to her. Pam. but I just. Do know that she's made contact with with retailers. About getting that off their shelves immediately Yeah, so it can be manufactured here, but shipped to other States. I don't know if Adam or Kate, or maybe even Shock knows about that. But but not sold here. Is that right? Nothing's bad, as far as I know. Yeah, I think that's right. It's it's a problem, though, because it's it's readily available over the Internet. So you know. And unfortunately, and I've I've never bought any delta products. But I I think with some of these websites, it's kinda like.

[108:00] you know, just says, Are you over 21? You click. Yes, and then then you can buy whatever you want on there. So it's it's unfortunate. But yeah, that's that's my understanding. Is that deltaid is not currently supposed to be sold within Colorado. And, Robin. do you have any insight? Because there's a group of parents that you you're probably aware of. Yeah, absolutely. I mean, I just really appreciate that. Anna took the time to write this letter and get into such specific detail about some of the things that these families in schools are struggling with, because I hear about it a lot, and I think that often many others who have different perspectives are not necessarily understanding the depth of some of these problems. And I appreciate this board. Taking a look at the letter and and thinking about these mo, a multi-dimensional place. Because this isn't all parenting problems. This isn't all. You know what's available on the Internet or through a head shop. Or.

[109:12] you know, secondary sales from dispensaries, because, believe me, that does happen. But there are major issues, and I think they're hard, and we have to talk about them, and I really hope that the Boulder police department in their investigation, and I hope Pam will follow up with us next time, because I was hoping she would be here. Some of the shops that are mentioned here are things that I know parents have been begging for help with for a while, so we really have to get some answers, because if we don't, it's like, what's the point? I'm happy. If anybody wanted to ask Anna questions right now she's on. I'm happy. I don't know if we'd have to take a vote on that. I thought she'd be able to answer questions, Tom, cause I feel like we've done that before with people. But maybe there was a nuance to the rule that I don't understand.

[110:11] We can ask Roberto, but I think if oh, go ahead, Kate. No, go ahead. Finish finish the conversation. If Rebecca in in the past. Yes, we have allowed people to speak at times other than the official public comment. You can certainly do so, but it would be for public comment. not for not for allowing questions of the board to the individual wanting to speak. In other words, she could make a statement of some sort if she wants to, but. Right. If the if you so desire to reopen the portion of public comment, you may do so. You just cannot engage.

[111:00] Hey? You were gonna say something. Well, I mean I I we're can we finish this topic? And then I can. Sure it wasn't about that. So for me. The the question that comes up for me is, we get a letter like this from a family that's having experience with cannabis in this community. What does the club do? What's our response to this? What's the next step on something like this? Because I feel like people don't know where to to necessarily go to get solutions. I mean, there might be an investigation by the Boulder police department, but I went to a meeting about 7 or 8 months ago, where Rob Anderson, who's the? He's a superintendent of Boulder Valley School district, said that cannabis has become a nightmare in school. That's something, he said. So I just feel like we're not necessarily engaging on a level of providing solutions

[112:06] in a really direct way. And I understand these are hard issues. These are. But this is happening in the community, and to the degree that you all can see that acknowledge it maybe leads us to a better place. Is this about Kate and Brian? Is this about that, or a different. Yeah, no, I well, I was. Gonna I was. Gonna I thought we were talking about whether or not we were gonna open public comment. And I didn't wanna interrupt that process. So I I decided not to comment. But I I do have a comment about this. Robin, do you know, if Anna wants to have 3 min. I don't know. Brian did, did you. Well, I I. Go ahead, Kate! That's fine! What I was gonna say was, I think, to to Robin's Point, I mean, like, this is something that I think we are as a board. We we. Our our job is not to. I think

[113:05] it's to advise right. It's to advise, not just on policy even, but on what what could be done right? And in terms of a response to this, we can't choose how the investigation goes. But we can ask what's going to happen. We can ask. You know, boulder, what what is? You know, what is going to be done, and what they're going to do? And we can kind of ask them to to provide us with an update. I think that you know, when we talk about like. what can we do from a like local schools. And, like all you know, I think the hardest thing and this is what we were talking about when Alison was on the board is is, we aren't responsible for the education we can't be, you know. And so it's like, How do we get the right tools? To different organizations? Or how do we get people, you know, to to to focus on that? Or how can we? You know what kind of policies can help to impact that I mean, I again, it's it's it's beyond sometimes the scope of what we have control over. You know, our, our things are kind of security within the the dispensary security and the product, and making sure that that the licensees

[114:10] can control what they can control. And this is beyond, I think, a step beyond that. I think there is the enforcement piece from from a city perspective. And I think that that's where we need Officer Dignac to be here to kind of have that conversation a little bit. And so I do think that that saying like, Hey, in in June's meeting, can we have a conversation about this like when you receive something like this, what is the process? What can you share with us? You know. And I think you know. I I I struggle with kind of you know, to your point, Robin, like what do we do as a board? We are the ones that need to to, to, not just draw attention, but also to like, say, this, this is obviously an issue, and it's not just in Colorado. You know, it's it's all over that I think it's trying to figure out how the policy can be, and that education can balance each other right, because I think they're moving into

[115:00] different paces. And that's kind of just how these things work, and also the the nuance of where cannabis is. And and So I think that we need to do something. And so, from from my perspective, I think yes, we need to have a conversation with Officer getting out to understand what happens after you receive something like this? And then maybe we have another conversation about what? What is it that we could do? You know from a you know, advisory perspective. But I do think that there is something about like we do need to understand what we can control from a licensee aspect. What can the businesses do? And then there is a separate part of that right. What can the city do? And I think we can also kind of helps influence both. Just knowing that they are separate things, and we only can create what we can create without kind of the help of of, you know, like boulder, public health and and Colorado public health. And yeah, getting that information from them.

[116:01] Go ahead, Brian. Yeah. So my, I sympathize deeply with sugars letter here, the kinds of challenges and the loopholes that she's confronting with trying to support her family. And so my question, perhaps to the city attorney's office, and maybe the licensing staff would be like if it is such common knowledge that there are licenses out there. Maybe not cannabis licenses, but other kinds of license businesses in the city city of color boulder that are, have these allegations against them, like, what is the best way that the community can go about creating? Doc documenting these allegations, reporting them to city staff for investigations like what is what is like the best way to document these allegations so that they can create a paper trail that can lead to investigations and hopefully, accountability and improvements.

[117:00] And if I can add to that question. I was just trying to think of an analogy, and I'm not sure it's a good analogy. But what the heck if we were the parks board, or the transportation board, or the where they ever have, like a historic preservation, or whatever they call that somebody had concerns. they'd have a go to right And this seems even more eminent than some of those that I just mentioned. Do we have a go? Do we have a obvious go to for concerned community members. Yeah, so it would be through our law enforcement officer. But they certainly do not have to go through you. They can go directly to the police department, and anytime that report is is, or anytime a complaint is made, a report is generated. and those reports are often reviewed, and I don't know if it's monthly or quarterly to see if there are trends in what areas. But the moment that there is probable cause to

[118:10] believe that a crime or or any sort of violation that would lead to a citation is before the Motor Police department. Then they would be doing the investigation. we might not know about it. Because oftentimes they will work with the state or other agencies in their investigations, and they will not disclose it until they are in a in a place where they can make those disclosures. But to answer the very specific question. go to law enforcement anytime. The community has an issue. If they come to us great, we have a law enforcement liaison, but they can certainly go directly to the law enforcement agency.

[119:02] Yeah. Well as you can tell from the letter. Miss Secure did that, and did not fail. like enough action was taken, and so actually, in the in the conversation with Aaron yesterday Aaron was gonna check in with the police chief and check the status of things. But I mean, it seems like. you know, teams are pretty smart. I was pretty smart when I was a team, so you know, they they figure out a way around these things, and I guess they are. They're somewhat creative, I guess it seems, but it's not to their advantage their long-run advantage. Go ahead, Adam. Yeah, I I was just gonna say I was. you know, certainly very sympathetic to Miss Seeger and what her family is going through, and and I think it was totally appropriate that she reported this stuff to to law enforcement. I I think you know, is good, that they

[120:04] did that, and I trust and hope that you know the police are are doing an investigation. I I personally, I'm a little skeptical about the idea that the dispensary is is selling directly to children. I'd I'd be awfully surprised if they were doing that just because the consequences can be so high. My my guess is that more likely there's someone who's 18 and has a medical card, or someone who's 21 who is buying for the kids? But you know again. I I don't know any of that for for a fact, and I think it's certainly very appropriate that that law enforcement look into it. And you know again, I would express a lot of sympathy to Miss Eager and what our family is going through. And I don't. The letter speaks for itself, but it sounds, I mean, and we heard from

[121:01] 4 parents yesterday. One of them I can't remember exactly which parent was, but their adolescent started doing concentrates like they were introduced at wrestling practice, or something like that, and it wasn't even known to the parents at the time, you know, that was supposedly a safe. You know, you would have expected things to be fine that you're you're adolescent wasn't gonna they were, they were, gonna you know, focus on a task at hand, but not be introduced to a drug which then caused cannabis induced psychosis and that person which and that's one thing I found alarming, that we have a whole list of new terms that even met students from 10 years ago didn't have to know. like cannabinoid hyperharmosis syndrome as as Robin has talked to us about? Or is cannabis induced psychosis?

[122:02] That's not a term I learned in Med school, or even. you know my schools, weren't they? Probably they might still not be teaching it. So I don't know. I'm just trying to get ahead of the game, so to speak. Robin. Thank you. I just wanna say that as a parent who, you know, went through a really extreme downside experience of having a child who became reliant on using this. These drugs. I know it's it's like horrifying. It's like watching an accident happen in slow motion, trying to tell people what's happening, what your experience is. and trying to get some attention on it. And that's why I really appreciate sharing of this letter. And what Anna shared with us. because the more people understand that for some

[123:02] users this drug can be incredibly harmful, and of course cannabis, hypermicis syndrome for a year was horrific for my kid. But cannabis-induced psychosis that then potentially turns into something long term is that's just a whole other beast. And there are people struggling with these very serious problems. And this isn't about being upset, that your kid is using drugs once in a while. This is different. This is a different level and to the degree that you all have been so gracious and courteous in thinking about this. I just wanna express my appreciation. And I think we have to continue talking about about these things and being aware of them. Cause this is happening right in our community. And again, when the superintendent says in a public meeting that marijuana has become a nightmare in the schools. That's something we have to talk about and think about. And I really appreciate Kate's comments on the conundrum of our particular board, and where we have sway or don't, and what the you know, sort of logical. Next steps are to take on something like this.

[124:12] but I do want to keep the conversation open and continue to stay very apprised of what's happening around us at the legislative level, or groups like the See you school of public health that talked to us today. And there are other really good people trying to do good work on this. Okay. Any further discussion. Adam. was waxing about whether she wanted to speak or not. To her. The the letter speaks for itself is how I would summarize it. Yeah. And and, Tom, there's other public comments on other meetings like, I don't. I don't think I I don't want to feel like we're forcing someone to talk when they've already do a whole lot.

[125:05] Yeah, I never want to do that. I can't like. I sometimes I think writing is easier than talking. So you know, I just wanna acknowledge that there are opportunities and to encourage people that want to talk, to, to talk during public on it. And those people who want to write do this. So I appreciate the city for kind of forwarding this onto us. So that we could, you know, talk about it. And I do think that we just we keep track of. I I think if I think about other boards right? Like, I think there is this, this sense of awareness. But then also, like, Well, what's happening? We can check in and see how things are going and ask questions about how the investigations going for what they can tell us. Obviously they can't tell us everything but we can check in and see where it's going, and we can continue to have a conversation about you know what we can do. You know, from a a policy standpoint and from a recommendation standpoint.

[126:04] But I think that you know I appreciate. you know the the the comment being shared. And yeah, I mean, I think, putting it on as a as a topic for for us to talk with officer gig next week would be helpful to just understand, maybe from an enforcement perspective, how how it's being responded to just for our our understanding of when we do get things like that, or when people do come forward to say that this happened, what, what steps are are being taken. Okay. any other any other suggestions. Josh, did you get a chance to talk to anybody else yet? I'm not. No.

[127:00] Ready to rally the troops for other topics that we and you and I talked about. Good afternoon. Just wait. I I can. I can wonder what what, what's that about. I mean this, yeah, so. Yeah, one on one with them. So. Right? Right? Gotta schedule that with everybody. Have a cup of coffee. Get to meet. Alright anything else. folks. Okay? So anybody want to make a motion to adjourn. Brian motions to adjourn. I'll second. Robin second, and I'll say, didn't note approval by saying I. I. Aye. Okay, I have it.

[128:00] Thanks and thanks. Staff. Steph, thank you. Board members. Thank you. Like Steph. Thanks, all right.